BARX1 promotes osteosarcoma cell proliferation and invasion by regulating HSPA6 expression-Reference-Cited by-同舟云学术

BARX1 promotes osteosarcoma cell proliferation and invasion by regulating HSPA6 expression

Published:2023-03-16 Issue:1 Volume:18 Page:
ISSN:1749-799X
Container-title:Journal of Orthopaedic Surgery and Research
language:en
Short-container-title:J Orthop Surg Res

Author:

Huang Xing,Wang Zhenhua,Zhang Jing,Ni Xiangzhi,Bai Guangjian,Cao Jiashi,Zhang Chunlei,Han Zhitao,Liu Tielong

Abstract

AbstractOsteosarcoma (OS) is a bone tumour affecting adolescents. Dysregulation of Barx homeobox 1 (BARX1) expression is involved in various cancers, but its function and mechanism in the process of OS are undefined. This study revealed that BARX1 expression is higher in OS tissue than in adjacent normal tissue. Downregulation of BARX1 in OS cells significantly suppressed their proliferation and migration, whereas enforced expression of exogenous BARX1 exerted the opposite effects on OS cells. Subsequently, heat shock 70-kDa protein 6 (HSPA6) expression was clearly increased after BARX1 overexpression in OS cells, as confirmed by RNA sequencing. The dual-luciferase reporter assay confirmed that HSPA6 expression is directly regulated by BARX1. The in vitro assay indicated that silencing HSPA6 expression attenuated OS proliferation and migration induced by BARX1. A dual immunofluorescence labelling assay provided further evidence that BARX1 was overexpressed and associated with HSPA6 overexpression in OS tumour tissue. In conclusion, BARX1 promotes OS cell proliferation and migration by inducing the expression of HSPA6, which plays an oncogenic role in OS. BARX1 and HSPA6 can potentially act as novel therapeutic targets for OS.

Funder

Liu Tielong

Publisher

Springer Science and Business Media LLC

Subject

Orthopedics and Sports Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1186/s13018-023-03690-z.pdf

Reference25 articles.

1. Lilienthal I, Herold N. Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: a review of current and future strategies. Int J Mol Sci. 2020;21:6885. https://doi.org/10.3390/ijms21186885.

2. Kelley LM, Schlegel M, Hecker-Nolting S, Kevric M, Haller B, Rossig C, Reichardt P, Kager L, Kuhne T, Gosheger G, Windhager R, Specht K, Rechl H, Tunn PU, Baumhoer D, Wirth T, Werner M, von Kalle T, Nathrath M, Burdach S, Bielack S, von Luttichau I. Pathological fracture and prognosis of high-grade osteosarcoma of the extremities: an analysis of 2,847 Consecutive Cooperative Osteosarcoma Study Group (COSS) Patients. J Clin Oncol. 2020;38:823–33. https://doi.org/10.1200/JCO.19.00827.

3. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–90. https://doi.org/10.1200/JCO.2002.20.3.776.

4. Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, Jundt G, Kabisch H, Reichardt P, Jurgens H, Gadner H, Bielack SS. Cooperative German-Austrian-Swiss Osteosarcoma Study, Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21:2011–8. https://doi.org/10.1200/JCO.2003.08.132.

5. Kim BM, Buchner G, Miletich I, Sharpe PT, Shivdasani RA. The stomach mesenchymal transcription factor Barx1 specifies gastric epithelial identity through inhibition of transient Wnt signaling. Dev Cell. 2005;8:611–22. https://doi.org/10.1016/j.devcel.2005.01.015.